Scholarlink

Objectives <p>Effective management of chronic kidney disease (CKD) in systemic lupus erythematosus (SLE) is crucial for reducing long-term complications. Sodium–glucose transport 2 inhibitors (SGLT2is) improve renal and cardiovascular outcomes of non-SLE-related CKD. We aimed to assess clinical characteristics and outcomes of SLE patients treated with SGLT2is.</p> Methods <p>This retrospective study evaluated adult SLE patients treated with SGLT2is for ≥ 3 months compared to untreated patients. Disease-related characteristics, kidney-related factors, and comorbidities were assessed. Repeated measures analysis model was applied to compare estimated glomerular filtration rate (eGFR) at different timepoints. Additional outcomes included infections, hospitalizations, and all-cause mortality. In SGLT2is-treated patients, eGFR and albuminuria were recorded before SGLT2is initiation, at 1 month, and 1 year following SGLT2is initiation.</p> Results <p>A total of 112 consecutive patients were included with a mean follow-up of 18.1 ± 12.7 years since SLE diagnosis. The use of SGLT2is in 9 SLE patients showed a stable kidney function over-time (60&#xa0;ml/min/m<sup>2</sup> ± 15 before treatment vs. 60 ± 17&#xa0;ml/min/m<sup>2</sup> at 1&#xa0;year of treatment, p = 0.5) and a trend toward reduction in proteinuria (450 ± 637&#xa0;mg/g before treatment to 279 ± 401&#xa0;mg/g at 12&#xa0;months following treatment, p = 0.07), without major adverse effects. No significant differences in cardiovascular events, infections, hospitalizations, or mortality rates were observed between treated and untreated patients.</p> Conclusions <p>This study suggests a potential benefit of SGLT2is in SLE patients. Further research is needed to confirm the nephro- and cardioprotective effects of SGLT2is in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical experience with sodium–glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Oshrat E. Tayer-Shifman,
  • Irina Kenis,
  • Sydney Benchetrit,
  • Dorin Bar-Ziv,
  • Yael Pri-Paz Basson,
  • Yair Levy,
  • Shaye Kivity,
  • Keren Cohen-Hagai

摘要

Objectives

Effective management of chronic kidney disease (CKD) in systemic lupus erythematosus (SLE) is crucial for reducing long-term complications. Sodium–glucose transport 2 inhibitors (SGLT2is) improve renal and cardiovascular outcomes of non-SLE-related CKD. We aimed to assess clinical characteristics and outcomes of SLE patients treated with SGLT2is.

Methods

This retrospective study evaluated adult SLE patients treated with SGLT2is for ≥ 3 months compared to untreated patients. Disease-related characteristics, kidney-related factors, and comorbidities were assessed. Repeated measures analysis model was applied to compare estimated glomerular filtration rate (eGFR) at different timepoints. Additional outcomes included infections, hospitalizations, and all-cause mortality. In SGLT2is-treated patients, eGFR and albuminuria were recorded before SGLT2is initiation, at 1 month, and 1 year following SGLT2is initiation.

Results

A total of 112 consecutive patients were included with a mean follow-up of 18.1 ± 12.7 years since SLE diagnosis. The use of SGLT2is in 9 SLE patients showed a stable kidney function over-time (60 ml/min/m2 ± 15 before treatment vs. 60 ± 17 ml/min/m2 at 1 year of treatment, p = 0.5) and a trend toward reduction in proteinuria (450 ± 637 mg/g before treatment to 279 ± 401 mg/g at 12 months following treatment, p = 0.07), without major adverse effects. No significant differences in cardiovascular events, infections, hospitalizations, or mortality rates were observed between treated and untreated patients.

Conclusions

This study suggests a potential benefit of SGLT2is in SLE patients. Further research is needed to confirm the nephro- and cardioprotective effects of SGLT2is in this population.